In 2021, Kenneth C. Frazier earned $16.15M in total compensation at Merck & Co., including $1.48M salary and $14.38M in stock. Most recently sold 235,769 shares in Nov 2022. Currently holds stock worth $75.43M. Has donated $29.40M in stock to charitable causes. Led Merck & Co. as CEO for 10 years.
Compensation History
Annual executive compensation data for Kenneth C. Frazier, including salary, bonuses, and stock awards.
Year
2021
Total Compensation
$16.15M
Salary
$1.48M
Bonus
$0.00
Other
$299.05K
Salary
$1.48MBoard Justification
Merck's compensation philosophy aims to attract and retain top talent while aligning executive pay with performance and shareholder interests, with a significant portion of compensation being variable and performance-based.
Bonus
$0.00Board Justification
No bonus was awarded for 2021 as part of the annual incentive plan.
Other Compensation
$299.05KBoard Justification
Other compensation includes financial and tax planning services, personal use of company aircraft, and other benefits as detailed in the proxy statement.
Restricted Stock
Board Justification
The stock awards that vested in 2021 were based on performance metrics established in prior years, specifically the 2019-2021 performance period, which resulted in a payout of 140%.
Performance Metrics
The performance metrics for 2021 included revenue, pre-tax income, and pipeline accomplishments, which were measured against the Company Scorecard.
Kenneth C. Frazier
Ex-CEO of Merck & Co.
Education
Not specified
Field of Expertise
Legal & Compliance - Law
Sector of Economy
Healthcare
Born
December 20, 1955 - 69 years ago
CEO of Merck & Co. for
10 years 5 months (Jan 2011 - Jun 2021)
Previous Experience
Executive Vice President and President, Global Human Health
Holdings
Track Kenneth C. Frazier's stock holdings and portfolio value over time.
Total Stock Sold
$459.40M
$459.40M
5,486,306 MRK shares
What if they kept their stock?
If Kenneth C. Frazier didn't sell their stock, today they would have:
Extra MRK5,486,306 shares worth $553.51M.
This is 20.49% and $94.11M more than what they got when they sold the stock.
Charitable Transactions
291,362 shares
MRK
Recent Charitable Transactions
5,630 shares
MRK
Nov 1, 2022
Charity
92,073 shares
MRK
Dec 31, 2020
Charity
118,764 shares
MRK
Dec 31, 2019
Charity
14,623 shares
MRK
May 6, 2019
Charity
18,747 shares
MRK
Jul 31, 2018
Charity
10,125 shares
MRK
Feb 27, 2017
Charity
Insider Trading
Kenneth C. Frazier's recent stock transactions, purchases, and sales filed with the SEC.
$23.42M
MRK at $99.31/share
Nov 7, 2022
Sale
$46.46M
MRK at $98.85/share
Nov 3, 2022
Sale
$60.11M
MRK at $100.19/share
Nov 1, 2022
Sale
5,630 shares
MRK
Nov 1, 2022
Charity
$86.89M
MRK at $100.21/share
Oct 28, 2022
Sale
$8.78M
MRK at $73.51/share
Feb 24, 2022
Received
$54.92M
MRK at $82.72/share
Nov 9, 2021
Sale
$12.73M
MRK at $72.62/share
Feb 26, 2021
Received
$22.79M
MRK at $81.41/share
Nov 9, 2020
Sale
92,073 shares
MRK
Dec 31, 2020
Charity
Rivals
Compare Kenneth C. Frazier with competitor CEOs and industry peers.
Albert Bourla
CEO of Pfizer
2024 Compensation
Stock
$0.00
Salary
$1.80M
Bonus
$7.02M
Other
$996.06K
Total Holdings
$18.14M
Daniel O'Day
CEO of Gilead Sciences
2024 Compensation
Stock
$18.79M
Salary
$1.77M
Bonus
$0.00
Other
$1.34M
Total Holdings
$23.48M
Joseph K. Belanoff, M.D.
Founder and CEO of Corcept Therapeutics
2023 Compensation
Stock
$0.00
Salary
$1.10M
Bonus
$1.32M
Other
$22.50K
Total Holdings
$21.20M
Joaquin Duato
CEO of Johnson & Johnson
2024 Compensation
Stock
$7.13M
Salary
$1.60M
Bonus
$3.22M
Other
$1.08M
Total Holdings
$1.09M
Stéphane Bancel
CEO of Moderna
2023 Compensation
Stock
$0.00
Salary
$1.58M
Bonus
$1.91M
Other
$1.07M
Total Holdings
$335.71M
Christopher Boerner
CEO of Bristol-Myers Squibb
2023 Compensation
Stock
$0.00
Salary
$1.50M
Bonus
$0.00
Other
$311.64K
Total Holdings
$7.39M